Bermekimab (MABp1) is a human monoclonal antibody that targets interleukin-1alpa (IL-1α). Bermekimab prevents tumour-related inflammation[1].
References
[1] McDonald JJ, et, al. Targeting IL-1α in cancer cachexia: a narrative review. Curr Opin Support Palliat Care. 2018 Dec;12(4):453-459. DOI:10.1097/SPC.0000000000000398